Posted by Michael Wonder on 11 Oct 2021
Tegsedi receives innovative drug category pricing in Brazil
11 October 2021 - PTC Therapeutics today announced that Tegsedi (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil.
Category 1 classification is given to innovative treatments that provide greater efficacy than current standards of care. Category 1 allows for pricing in line with international markets.
